Delaying or preventing the complications of Type-1 diabetes by adding the selective mineralocorticoid receptor antagonist eplerenone to standard medication for patients with Type-1 Diabetes.

Trial Profile

Delaying or preventing the complications of Type-1 diabetes by adding the selective mineralocorticoid receptor antagonist eplerenone to standard medication for patients with Type-1 Diabetes.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BART-1
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top